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Abstract
The use of interleukin-7 (IL-7) as an immunorestorative therapeutic has proven effective in
HIV infection, cancer and bone marrow transplantation. Mediating its activity through mem-
brane-bound IL-7 receptor α (mCD127), IL-7 therapy increases T-cell numbers and survival.
A soluble form, sCD127, is found in plasma, and we have previously identified increased
plasma sCD127 concentrations in HIV infection. Furthermore, patients with high sCD127
exhibited the best viral control, implicating a role for IL-7 or sCD127 directly in improved viro-
logic/immunologic outcomes. The role of the cytokine IL-7 in elevating sCD127 levels was
addressed here through assessment of retrospective samples obtained from SIV-infected
antiretroviral (ART)-treated Rhesus macaques. IL-7 was administered in clustered weekly
doses, allowing for an assessment prior, during and following IL-7 administration. The levels
of sCD127 remained relatively unchanged during both early SIV infection and following
initiation of ART. However, treatment with IL-7 increased sCD127 concentrations in most
animals, transiently or persistently, paralleling increased T-cell numbers, correlating signifi-
cantly with CD8+ T-cell levels. In addition, proliferating CD4+ or CD8+ T-cells (measured by
Ki67) increased in association with elevated sCD127 concentrations. Finally, a high concen-
tration of sCD127 in IL7-treated animals was associated with increased retention of T-cells
(measured by BrDU). In addition, a lack, or loss of viral control was associated with more
pronounced and frequent elevations in plasma sCD127 concentrations with IL-7 therapy. In
summary, plasma sCD127 levels in SIV-infected ART-treated macaques was associated
with therapeutic IL-7 administration, with higher sCD127 levels in macaques demonstrating
the best T-cell responses. This study furthers our knowledge regarding the interrelationship
between increased IL-7 levels and elevated sCD127 levels that may have implications for
future IL-7 immunotherapeutic approaches in HIV-infected patients.
PLOS ONE | https://doi.org/10.1371/journal.pone.0188427 December 19, 2017 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Steele AK, Carrasco-Medina L, Sodora
DL, Crawley AM (2017) Increased soluble IL-7
receptor concentrations associate with improved
IL-7 therapy outcomes in SIV-infected ART-treated
Rhesus macaques. PLoS ONE 12(12): e0188427.
https://doi.org/10.1371/journal.pone.0188427
Editor: Cristian Apetrei, University of Pittsburgh
Centre for Vaccine Research, UNITED STATES
Received: July 31, 2017
Accepted: November 7, 2017
Published: December 19, 2017
Copyright: © 2017 Steele et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are available
from https://doi.org/10.5061/dryad.72c40/1.
Funding: This work was supported by National
Institutes of Health Grants R01-AI035522 (to D.L.
S.), R01-DE017541 (to D.L.S.) (https://www.nih.
gov/); Oregon National Primate Research Center
Core Grant P51-RR00163 (http://www.ohsu.edu/
xd/research/centers-institutes/onprc/); James B.
Pendleton Charitable Trust (to D.L.S.) (https://
fconline.foundationcenter.org/grantmaker-profile/?
key=PEND010&view_format=compact); The
Introduction
Interleukin-7 (IL-7) regulates the homeostasis of mature T-cells by inducing cell proliferation
and promoting cell survival by altering the balance between pro- and anti- apoptotic proteins.
IL-7 has been shown to increase the expression of anti-apoptotic proteins (e.g. Bcl-2) and
decrease pro-apoptotic protein expression (e.g. Bad and Bax)[1–5]. Given its role in T-cell
homeostasis, IL-7 immunotherapy has been widely applied to diseases in which T-cells may
play a role. Therapeutic administration of IL-7 has been evaluated for the treatment of cancer
[6], chronic HIV infection[7, 8] and transplantation[9] in which T-cell reconstitution is
required. IL-7 therapy is also under consideration for the treatment of bacterial-mediated sep-
sis and parasitic infections[10–13]. Clinical trials conducted in bone-marrow transplant and
cancer patients, indicated that IL-7 therapy increased T-cell expansion, survival, thymic out-
put, and T-cell receptor repertoire diversity[14, 15]. In an attempt to address T-cell deficiencies
in human immunodeficiency virus (HIV) infection, studies evaluated the effects of IL-7 ther-
apy in humans and the non-human primate model of simian immunodeficiency virus (SIV).
Findings suggest that IL-7 immunotherapy has a net positive effect with regard to increasing
T-cell numbers and survival[7, 8] and in SIV-infected Rhesus macaques, IL-7 therapy aided to
overcome IFN-α treatment-induced lymphopenia[16].
Regulation of IL-7 activity on T-cells can occur by the altered expression of its receptor,
composed of the IL-7 receptor α (CD127) and the IL-2 receptor α chains[17], the latter of
which exists in a membrane-bound form (mCD127) and as a soluble receptor (sCD127).
The expression of mCD127 varies in thymic development and T-cell responses, with pro-
nounced downregulation on effector cells. We also know that mCD127 expression on T-cells
is reduced by IL-7, paralleling cell cycle progression, and that CD8+ T-cells subsequently
release sCD127[18]. Expression of mCD127 on T-cells is significantly reduced in HIV infec-
tion and recovers to near normal concentrations with highly active antiretroviral therapy
(HAART)[19–21]. In addition, we and others have found that plasma sCD127 concentrations
are increased in HIV infection, are associated with a more rapid HIV disease progression and
plasma sCD127 concentrations are not lowered with successful HAART treatment[18, 22–25].
Whether the release of this receptor from cells accounts in part for the reduction in mCD127
in health and disease, and hence a means of regulating IL-7 signaling to a cell, remains to be
determined. It was thought that sCD127 may act as a decoy receptor and suppressor of cyto-
kine signaling, however we and others have recently demonstrated that pre-incubating T-cells
with recombinant sCD127 enhanced IL-7 activity in murine models and cultures of human or
mouse T-cells[26, 27]. Carini et al., detected more sCD127 in the culture supernatants of
PBMC collected from HIV+ individuals with undetectable HIV-specific CTL activity com-
pared to those with detectable CTL activity[24], suggesting that sCD127 may influence CTL
function in vivo. The factors and mechanisms mediating the release of sCD127 are not entirely
understood, but it is known that IL-7 induces the release of sCD127 from CD8+ T-cells[8]
while mCD127 is downregulated[18], and this may be mediated by proteolytic cleavage of the
receptor (Angel, J.B., personal communication, unpublished)[28]. The role of sCD127 in the
effects of IL-7 immunotherapy is not known.
Based on our previous research which identified an increase in plasma sCD127 in HIV
infection, and our preliminary understanding of how IL-7 induces sCD127 release from T-
cells[18, 29], we questioned the effect of IL-7 therapy on plasma sCD127 concentrations, and
whether the soluble receptor was associated with the therapeutic effects of IL-7 on T-cells in
HIV infection. The Rhesus macaque/SIV infection model is one of the mainstays of HIV
research. Disease progression in macaques is closely analogous to disease progression in
humans and is characterized by high viral loads, rapid mucosal T-cell loss, gradual peripheral
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T-cell depletion, and eventual progression to simian AIDS[30, 31]. In this model, studies have
revealed how the progressive loss of certain T-cells subsets, or their impaired function, contrib-
utes to AIDS progression. Previously, IL-7 has been tested as an immunotherapeutic in SIV-
infected macaques being treated with anti-retroviral drugs, analogous to chronically infected
HIV patients, and resulted in the expansion of relevant CD4+ and CD8+ T-cell populations[32,
33]. Leone A. (now Steele, A.) et al. demonstrated that a clustered dosing regimen of glycosy-
lated recombinant simian IL-7 (rsIL-7gly) induced the proliferation of CD4+ and CD8+ central
memory and naïve cells, increased T-cell survival and sustained elevation of peripheral CD4+ T-
cell counts in ART-treated SIV-infected Rhesus macaques[34]. Clinical studies in HAART-
treated HIV+ patients have had similar outcomes[7, 8]. Therefore, we retrospectively quantified
sCD127 concentrations in plasma samples collected from our previously published study[34] to
determine for the first time whether sCD127 release is altered in early SIV infection, (2) whether
antiretroviral (ART) reversed any such change, (3) to test the effect of exogenous IL-7 on the
release of its receptor in vivo, and (4) to test whether plasma sCD127 concentrations were asso-
ciated with the therapeutic effects of IL-7 on T-cells in the treatment of chronic viral infection.
This study provides key insights regarding increased IL-7 levels and elevated sCD127 levels that
may have implications for future IL-7 immunotherapeutic approaches in HIV-infected patients.
Methods
Animal research ethics statement
The animals in this study were housed at the Oregon National Primate Research Center
(ONPRC). This work received prior approval by the Institutional Animal Care and Use Com-
mittee (IACUC) of ONPRC IACUC approved protocol (IACUC #492–02: “Immune Reconsti-
tution in SIV Infected Macaques”). IACUC proposals include a written scientific justification
for any exclusions from some or all parts of the plan. In addition, this study was performed in
strict accordance with 1) the recommendations in the Guide for the Care and Use of Labora-
tory Animals of the National Institutes of Health, a national set of guidelines in the U.S., 2)
international recommendations detailed in the Weatherall Report (2006) and 3) in accordance
with the ONPRC Institutional Animal Care and Usage Committees, accredited by American
Association of Accreditation of Laboratory Animal Care. Rhesus macaques are fed standard
monkey chow (Jumbo Monkey Diet 5037, Purina Mills, St Louis, MO) twice daily. Consump-
tion was monitored and adjustments were made as necessary depending on sex, age, and
weight so that animals received sufficient food without creating excessive food waste. SIV-
infected Rhesus macaques were housed in adjoining individual primate cages allowing social
interactions and participation in enrichment activities, under controlled conditions of humid-
ity, temperature and light (12-hour light/12-hour dark cycles). Appropriate procedures were
performed to ensure that potential distress, pain, discomfort and/or injury was limited to that
unavoidable in the conduct of the research plan. All enclosures and animal rooms were
cleaned daily with water and sanitized at least once every two weeks. The sedatives Ketamine
(10 mg/kg) and/or Telazol (4 mg/kg) were applied as necessary for blood collections and
analgesics were administered as appropriate by the veterinary medical staff. If an animal had
developed a disease state that was not clinically manageable, the animal would have been
euthanized in accordance with the recommendations of the Panel on Euthanasia of the Ameri-
can Veterinary Medical Association (AVMA). No animals were euthanized before the latest
time points used in the present study. These animals were included in parallel projects and
were euthanized using sodium pentobarbital. Euthanasia was ensured by exsanguination and
bilateral pneumothorax, consistent with the recommendations of the AVMA Guidelines on
Euthanasia (June 2007).
Soluble IL-7R alpha and IL-7-mediated immune restoration
PLOS ONE | https://doi.org/10.1371/journal.pone.0188427 December 19, 2017 3 / 19
Animal study design
A schematic of the experimental design is shown in Fig 1. A total of 9 Rhesus macaques were
analyzed in this study, many of whom were the subject of a previous study by Leone A. (now
Steele, AK) et al.[34] All animals were infected with SIVmac239, i.v. using 5 ng equivalents
of SIV p27 (1.03105 infectious centers) (day 0), treated with ART (105 days post-infection
(d.p.i.)). All animals were started on 9-R-2-phosphonomethoxypropyl adenine (PMPA)
(30mg/kg) and emtricitabine (FTC) (50mg/kg) for 4 weeks. The ART was then reduced to a
maintenance dose (PMPA 20mg/kg; FTC 50mg/kg).
Following SIV infections, animals were divided into a control group (n = 4) or IL-7-treated
group (n = 5). The IL-7 treatment group was administered 3 clusters of rsIL-7gly (30mg/kg,
Cytheris) administered s.c. weekly for 3 weeks followed by 2 weeks between each cluster. The
control group consisted of animals RM23092, RM23699, RM23788 (previously RM2-06 in
Leone et al., 2010) and RM23892. The IL-7-treated animals were RM22657 (previously RM2-
05), RM23201 (previously RM2-07), RM23686, RM23750 and RM24090.
T-cell phenotyping and related immunoassays
Cells were phenotyped by flow cytometry as described in the previously published study[34].
The present study referred specifically to naïve, central and effector memory cell subsets
identified as follows: naïve (TN, CD28intCD95lowCCR7intCCR5-), central memory (TCM,
CD95hiCD28hiCCR7+CCR5-), transitional effector memory (TTrM, CD28
hiCCR5+ and/or
CCR7-) and fully differentiated effector memory (TEM, CD95
hiCD28-CCR7-CCR5dim+). T-cell
activation was determined by assessing Ki67 expression by flow cytometry. Lastly, the reten-
tion of T-cells was determined by enumerating the number of BrdU+ cells following in vivo
labeling with BrdU, as described previously[35].
Quantification of plasma sCD127 concentrations
Plasma samples used in this study corresponded to specific time points prior to SIV infection,
after ART initiation, and during the period of IL-7 administration. All plasma samples were
treated with Triton-X (0.1%) at 37˚C for 1 hour to neutralize viral particles, and then diluted
to 1/10 in PBSBN buffer (PBS + 1% BSA+ 0.05% NaN3).
To quantify the concentration of sCD127 in Rhesus macaque plasma, a CD127-specific
antibody-microfluorosphere MagPix assay was adapted from the original human CD127-spe-
cific Luminex assay[36] that was found to cross-react with simian CD127. The goat anti-
human CD127 capture antibody (R&D Systems) was coupled to MagPix beads (Luminex,
MC10025-01) using the XMAP antibody coupling kit (Luminex) and following the manufac-
turer’s instructions. Briefly, 1.7x107 microspheres were coupled to 80 μg of capture antibody
Fig 1. Study design for the SIV infection, antiretroviral treatment and IL-7 therapy administration of
Rhesus macaques. Animals were infected with SIV at day 0, and antiretroviral (ART) was initiated 105 days
post-infection (d.p.i), with a dose reduction 128 d.p.i. Animals who were administered rsIL-7-gly received 3
clusters of rsIL-7gly administered s.c. weekly for 3 weeks followed by 2 weeks between each cluster. All
animals were administered BrDu daily for 4 days, starting 149 d.p.i. Each vertical line corresponds to date on
which a collected plasma sample was utilized for the quantification of sCD127 in this study.
https://doi.org/10.1371/journal.pone.0188427.g001
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and stored at 1.x107 beads/ml in the dark at 4˚C until needed. A Bio-Plex Pro 96-well flat bot-
tom plate (Bio-Rad, 171–025001) was pre-wet with 200 μl/well of PBST (PBS + 0.05% Tween
20 + 0.05% NaN3). Following a soak-aspirate wash on the automated Bio-Plex Pro II wash sta-
tion, 50 μl/well of PBST + 50 μl/well of MagPix-coupled capture antibody (6x104 beads/ml)
were added. A soak-aspirate wash was repeated, followed by 3 dispense-soak-aspirate cycle
washes of 200 μl/well of PBST. Then, 50 μl/well of sample/well was added and plate was shaken
(800 rpm) for 2 hours at room temperature. The wash steps above were repeated. The detec-
tion antibody was added (50 μl/well, biotinylated mouse anti-human CD127, 20.4 μl/ml of
PBSBN, BD Pharmingen) and the plate was shaken (800 rpm) for 1 hour at room temperature.
Following repeated washing, 50 μl/well of streptavidin R-phycoerythrin conjugate (1/500 in
PBSBN, Invitrogen) was added and the plate was shaken (800 rpm) for 10 minutes at room
temperature. The plate was washed and 125 μ/well of 2% paraformaldehyde was added, fol-
lowed by shaking the plate at 1000 rpm for 60 seconds. Bi-fluorescent complexes were then
detected with the Bio-Plex reader and Bio-Plex Manager 6.0 software (BioRad). The concentra-
tion of sCD127 in plasma samples was determined by extrapolating their fluorescent readings
from a standard curve of recombinant sCD127 Fc-chimeric protein (1–500 ng/ml) prepared in
a 1/10 dilution of sCD127 negative plasma. Positive controls for this assay included 1:1 and 1/
10 dilutions of culture supernatant collected from WI-26VA4 cells, known to secrete sCD127
[37].
Data analyses
All data sets were graphed using GraphPad Prism software 5.0 (GraphPad). A paired one-way
Student’s t-test or ANOVA followed by a Kruskal-Wallis non-parametric post-test were used
as appropriate to detect statistically significant changes in plasma sCD127 concentration. Data
pertaining to viral load, T-cell numbers, activation state (Ki67+/-), and survival were extracted
from the study files associated with the Leone A et al. study[34], and its associated PhD thesis.
The extracted data was used in correlation studies with the measured sCD127 concentrations.
The Spearman rank correlation test was used to determine whether there was a significant
association between two variables. Multiple regression coefficient analyses were used to detect
significant associations between sCD127 concentrations and T-cell parameters over time using
XLSTAT (Addinsoft, New York, NY, USA). All raw data can be found on the Dryad online
filesharing platform (DOI: https://doi.org/10.5061/dryad.72c40/1).
Results
Plasma sCD127 concentrations are not altered by SIV infection or ART
To determine the effect of SIV infection on plasma sCD127 concentrations, an immunobead
assay was used to quantify the concentration of this soluble receptor in plasma collected from
Rhesus macaques prior to, and immediately following primary SIV infection. Pre-infection,
the concentration of plasma sCD127 varied from undetectable to 25.79 ng/ml (±7.4 S.D.,
n = 9). The concentration of plasma sCD127 was not significantly altered at 56 or 105 d.p.i.
compared to day 0 (analysed by two-tailed Student’s t-tests), suggesting that early SIV infec-
tion did not significantly alter sCD127 expression (Fig 2A).
ART was initiated 105 d.p.i and did not significantly alter plasma sCD127 concentrations at
126 and 142 d.p.i. in the control group (n = 4, Fig 2A). The plasma concentrations of sCD127
remained unchanged long-term (i.e. up to 394 d.p.i., ANOVA and Kruskal-Wallis post-test) in
the control macaques that did not go on to receive IL-7 therapy (Fig 2A). This result was inde-
pendent of viral load, although all animals in the control group failed to suppress SIV viral
loads with ART (Fig 2B).
Soluble IL-7R alpha and IL-7-mediated immune restoration
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Soluble CD127 increases with IL-7 treatment in ART-treated SIV+
Rhesus macaques
Given that IL-7 has been shown to induce the release of CD127 from human T-cells, the effect
of IL-7 therapy on the concentration of plasma sCD127 was investigated in the SIV-infected
Rhesus macaques. Administration of IL-7 did not lead to consistent significant increases in
the mean sCD127 concentrations at any time point (p> 0.05 by ANOVA, Fig 3A). Monitoring
of plasma SIV viral loads throughout the IL-7 treatment periods found that RM22657 main-
tained viral control, and RM24090 failed to suppress, while RM23201 (191 d.p.i), RM23686
(134 d.p.i) and RM23750 (134 d.p.i) lost viral control (at the indicated dates post-infection)
(Fig 3B). Based on the responses of individual animals, it appeared that the degree of viral sup-
pression may have affected the changes in sCD127 concentrations in response to IL-7 therapy.
For example, RM22657 (Fig 3C), who transiently increased sCD127 in only one cluster, had
an undetectable viral load (< 50 copies/ml) as of 170 d.p.i. on ART. Animals who were sup-
pressed but lost viral control when the ART dose was changed (RM23201 [Fig 3D], 23686 [Fig
3F], and RM23750 [Fig 3G]) had increased sCD127 concentrations in either cluster 2 or 3
when the viral load had fully rebounded. Finally, RM24090, who transiently increased sCD127
in response to all three IL-7 clusters, failed to suppress viral load on ART (22 x 106 copies/ml,
142 d.p.i.) at any time point (Fig 3E). In addition, the magnitude of the sCD127 burst in
RM24090 increased with each treatment cluster. Thus, in individual animals, the lack of viral
control tended to increase the magnitude and frequency of sCD127 increases in response to
IL-7 therapy.
While there was no statistically significant increase in sCD127 concentrations in a group
analysis (Fig 3A), each of the five IL-7-treated macaques responded to at least one cluster of
IL-7 doses with transiently increased concentrations of sCD127. RM 24090 (Fig 3E) was the
Fig 2. Plasma sCD127 concentrations are unaffected by SIV infection or antiretroviral therapy in Rhesus macaques. The concentration of
sCD127 in plasma samples of Rhesus macaques prior to SIV infection, after infection, following ART initiation (>105 d.p.i.) was determined using a
CD127 microbead immunoassay. The minimum detection limit of the immunoassay is 5 ng/ml. (A) Plasma concentrations of sCD127 did not change
following SIV infection or after ART (paired Student’s t-test, n = 4) in the control group. (B) The concentration of plasma sCD127 (mean, +/- SD) is
shown relative to viral loads for each animal in the control group over time (0–380 d.p.i.). Plasma samples for RM23892 (day -7 until day 105 post-
infection) could not be located for the quantification of sCD127 in this retrospective study.
https://doi.org/10.1371/journal.pone.0188427.g002
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Fig 3. Plasma sCD127 concentrations increased and persisted after IL-7 administration to ART-treated SIV-infected Rhesus macaques. The
concentration of sCD127 in plasma samples of Rhesus macaques prior to SIV infection, after infection, following ART initiation (>105 d.p.i.) and after
each administration of IL-7 (started at 142 d.p.i.) was quantified by a CD127 microbead immunoassay (min. detection limit: 5 ng/ml). (A) Plasma
sCD127 concentrations transiently increased in all SIV-infected, ART-treated animals that were administered rsIL-7-gly (n = 5). In some cases, these
increases persisted for 3–5 weeks. (B) The concentration of plasma sCD127 (mean, +/- SD) is shown relative to viral loads for each animal in the IL-
7-treated group over time (0–380 d.p.i.). (C-G) Changes in sCD127 concentrations also varied by IL-7 cluster, depending on the individual. In the first
cluster of IL-7 administration, 3 of 5 animals (C, D and E) demonstrated a sharp increase in plasma sCD127 concentrations before the next cluster.
The second cluster of IL-7 treatment increased sCD127 release in 2 animals (E and G). Plasma sCD127 concentrations increased in the third cluster in
3 of 5 animals (D, E and G). Transient increases in plasma sCD127 concentrations persisted for as long as 3–5 weeks following the last administration
of IL-7 in a given cluster. Lastly, the magnitude and frequency of observed increases in sCD127 concentrations was most pronounced in animals that
either (C) failed to suppress the virus with ART or (D, F and G) lost virological control, compared to (C) the virologically suppressed animal. The
clustered administration of IL-7 is indicated on the x-axis by groups of three arrows labeled as clusters #1–3.
https://doi.org/10.1371/journal.pone.0188427.g003
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most responsive to IL-7 administration and showed transient increases in sCD127 following
all three IL-7 clusters. RM23201 (Fig 3D) transiently increased sCD127 concentrations follow-
ing two of the three IL-7 clusters, and RM22657 (Fig 3C), RM23686 (Fig 3F), and RM23750
(Fig 3G) transiently increased sCD127 following one of the three IL-7 clusters. In some cases,
the transient increase in plasma sCD127 concentrations persisted for as long as 3–5 weeks fol-
lowing the last administration of IL-7 in a given cluster. Therefore, IL-7 therapy appeared to
induce transient increases in plasma sCD127 concentrations in SIV-infected, ART-treated
Rhesus macaques.
Plasma sCD127 correlates with IL-7effects on CD8+ T-cell numbers in
ART-treated SIV+ Rhesus macaques
In the control animals, there was no significant correlation between the sCD127 concentration
and the absolute CD4+ or CD8+ T-cell numbers (Spearman correlation analysis) in early SIV
infection (before 105 d.p.i.). There were also no significant associations between sCD127 con-
centrations and the absolute numbers of CD4+ or CD8+ T-cells from 142–247 d.p.i. when time
was taken into account in a multiple regression coefficient analysis. Therefore, in the context
of ART alone, the concentrations of sCD127 in the plasma did not appear to be correlated
with the absolute number of total CD4+ or CD8+ T-cells.
In contrast, in the macaques treated with IL-7, there were distinctive features in the changes
in sCD127 concentrations and absolute CD8+ T-cell numbers during the IL-7 treatment
period. Taking a more granular approach, and again focusing on the responses of individual
animals, RM24090 (Fig 4A) had the most apparent association between sCD127 concentra-
tions and total CD8+ T-cell numbers. In this animal, both the plasma sCD127 concentration
and T-cell number increased in response to each cluster of IL-7. The animals that lost control
of their viral load (RM23201 [Fig 4B], RM23686 [Fig 4C], and RM23750 [Fig 4D]) also had
some degree of overlap between increased plasma sCD127 concentrations and increased total
CD8+ T-cells in response to specific IL-7 clusters. In contrast, there was no visible relationship
between sCD127 and CD8+ T cell numbers in RM22657 who maintained viral suppression. In
this animal, the single increase of sCD127 in cluster 1 was not coupled by an increase in the
absolute T-cell numbers (Fig 4E). In contrast, assessment of sCD127 plasma levels and total
CD4+ T-cell numbers during IL-7 therapy did not exhibit a significant correlation (Spearman
rank correlation test, r = 0.345, p = 0.066). There was an overall strong, positive correlation
between sCD127 concentrations and total CD8+ T-cell numbers (Fig 5A, Spearman, r =
0.3193, p = 0.035) during the IL-7 treatment period (142–254 d.p.i). Among the CD8+ T-cell
subsets, this was found to most significant in the TN (r = 0.340, p = 0.024, Fig 5B), TTRM
(r = 0.439, p = 0.003 Fig 5C) and TCM (r = 0.505, p = 0.035, Fig 5D) cells. There was no signifi-
cant correlation between sCD127 and the absolute numbers of CD3+, CD4+ or TEM CD8
+ T-
cells during the IL-7 treatment period. When taking time into account, increased sCD127 con-
centrations significantly correlated with increasing absolute CD8+ T-cell numbers over the
course of the IL-7 treatment (multiple regression coefficient analysis, r = 0.490, p = 0.004).
This was particularly evident in the same CD8+ T-cell subsets as in the previous analysis: TN
(r = 0.708, p< 0.001), TTRM (r = 0.421, p = 0.018) and TCM (r = 0.519, p = 0.002).
Plasma sCD127 concentrations associate with IL-7-mediated activation
of T-cells in ART-treated SIV+ Rhesus macaques
In this cohort of macaques, T-cell activation (% Ki67+) was significantly increased in response
to IL-7 and mirrored the observed increases in the absolute numbers of T-cells[34]. To further
characterize the role of sCD127 concentrations in T-cell activation, the correlation between
Soluble IL-7R alpha and IL-7-mediated immune restoration
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changes in plasma sCD127 concentrations and the number of Ki67+ T-cells following the initia-
tion of IL-7 treatment was evaluated. Due to the retrospective nature of the study, this data was
only available for 4 of the 5 animals treated with IL-7, as analyzed in the TEM and TCM subsets.
Given the individual variation in sCD127 concentrations and the percentage of activated
memory CD4+ and CD8+ T-cell subsets, there was no detectable significant correlation
between sCD127 and the percentage of Ki67+ CD4+ T-cells (Fig 6A–6D) or CD8+ T-cells (Fig
7A–7D). However, on an individual concentration, in 3 of the 4 animals for whom this data
was available, sCD127 concentrations increased in parallel with changes in Ki67+CD4+ TN
and TCM cell numbers: RM22657 in the first cluster of IL-7 treatment (156 d.p.i., Fig 6A);
RM23686 in the second cluster increased sCD127 concentrations between 184–212 d.p.i.,
prior to an increase in the number of these T-cell subsets (Fig 6C); and RM23750 showed an
increase of plasma sCD127 in cluster 3 (212–226 d.p.i.) in tandem with increasing Ki67+ TN
and TCM CD4
+ cells (Fig 6D).
The concentration of sCD127 also increased in parallel with the number of activated CD8+
TEM cells in all 4 animals for whom this data was available (Fig 7): at 156 d.p.i., plasma sCD127
concentrations rebounded in RM22657 (Fig 7A) and RM23201 (Fig 7D) when Ki67+CD8+
TEM cell numbers increased; increasing sCD127 concentrations in RM23686 during 181–212
d.p.i. occurred before a subsequent burst in activated CD8+ TEM cell numbers 219 d.p.i. (Fig
7B); and lastly, sCD127 concentrations increased in RM23750 between 212–226 d.p.i. when
cell activation increased 226 d.p.i. (Fig 7C).
Fig 4. Increased plasma sCD127 concentrations correlated with IL-7-induced increases in CD8+ T-cells in SIV-infected Rhesus macaques.
(A-D) Representative graphs of IL-7-treated animals whose concentration of plasma sCD127 increased with changes in absolute CD8+ T-cell numbers
in at least one IL-7 cluster during the cytokine treatment time period. (E) In the animal that maintained viral control, plasma sCD127 concentrations did
not appear to associate with changes CD8+ T-cell numbers. Total number of IL-7-treated animals in which data of absolute T-cells was available: n = 5.
The clustered administration of IL-7 is indicated on the x-axis by groups of three arrows.
https://doi.org/10.1371/journal.pone.0188427.g004
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Plasma sCD127 may contribute to IL-7-mediated retention of T-cells
The survival of the T-cells proliferating in response to IL-7 therapy in vivo was assessed in this
cohort of macaques using BrdU labeling. The animals received BrDU for 4 days beginning
seven days after the first dose of IL-7 therapy (i.e. 149 d.p.i). Retention (i.e. survival) of prolifer-
ating cells was defined as detection of BrdU+ cells over time, reflecting an increased half-life
for labeled cells. IL-7 therapy increased the retention of memory T-cells in SIV+ ART-treated
Rhesus macaques, indicating a survival benefit in addition to a proliferative effect[34]. In this
study, we hypothesized that the release of sCD127 may have been related to the cell survival
effects observed with IL-7 therapy. In control animals, the number of BrDU+ memory CD4+
or CD8+ T-cells were less than an arbitrary yet common crossing point of 5 cells/μl of blood
within 2 weeks of BrdU administration (CD4 memory mean 16.5 ±9 days post-BrdU; CD8
memory mean 23.5 ±19 days post-BrdU, Fig 8). However, given that the concentration of
sCD127 was low and not altered in the control animals, it was not possible to evaluate a rela-
tionship between sCD127 concentrations and memory T cell survival in this population.
Therefore, our analyses focused exclusively on the IL-7-treated group.
When analyzing individual responses to IL-7 treatment, there was some evidence that
sCD127 concentrations were associated with the persistence of BrDU-labeled cells. Coincident
with the increase in sCD127 concentrations in IL-7-treated Rhesus macaques compared to
those treated with ART only (Fig 2A compared to 3A), a significant survival benefit was
observed in all IL-7-treated animals, as shown by the delayed loss of BrDU+ cells (Fig 9). In
contrast to the ART-treated control group, animals receiving ART + IL-7 treatment retained
Fig 5. Increased plasma sCD127 concentrations correlated with IL-7-induced increases in CD8+ T-cell subsets in SIV-infected Rhesus
macaques. All CD8+ T-cell subsets with statistically significant correlations with sCD127 are graphed here. Increasing concentrations of plasma
sCD127 following IL-7 administration were positively correlated with increases in (A) total, (B) naïve TN, (C) transitional effector memory TTrM and (D)
central memory TCM CD8+ T-cell subsets in SIV-infected, ART-treated Rhesus macaques (Spearman correlation analysis, r- and p-values are
indicated on graphs).
https://doi.org/10.1371/journal.pone.0188427.g005
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at least 5 BrDU+ cells/μl of blood as late as 254 d.p.i. The degree of viral suppression also
appeared to influence sCD127 concentrations in relation to when the number of BrDU+ cells
fell below the 5 cell/uL threshold. Among the four animals who either lost viral control or
failed to suppress viremia on ART and had high concentrations of sCD127, three recorded < 5
BrDU+ CD8+ cells/uL by 212 d.p.i.: RM23201 (Fig 9B), RM23686 (Fig 9C) and RM23750
(Fig 9D). This was considerably sooner than the animal with full virological control
(RM22657, Fig 9A) whose CD8+ T-cell numbers were below this minimum after 240+ d.p.i.
This animal had intermediate concentrations of sCD127 that did not fluctuate over time.
Discussion
Therapeutic administration of IL-7 has the potential to restore T-cell numbers and increase cell
survival[7, 8, 15]. The present study has found that plasma sCD127 concentrations parallel
these outcomes in SIV-infected, ART-treated Rhesus macaques administered IL-7. Repeated
injections of IL-7 resulted in transiently increased concentrations of sCD127 that were affected
by the degree of viral suppression in each animal. These increases in sCD127 concentrations
associated with IL-7-induced increases in the absolute numbers and number of activated CD8+
and CD4+ T-cells. The increases in plasma sCD127 were also associated with IL-7-enhanced T-
cell survival, while having an inverse relationship with T-cell retention over time following IL-7
treatment. These data show for the first time that a parallel increase in plasma sCD127 concen-
trations with IL-7 therapy is a biomarker for increased numbers and survival of T-cells in the
ART-treated SIV infection model.
In IL-7-treated animals, poor viral control was also associated with a greater increase in
sCD127 as well as how often a given animal experienced an increase in sCD127 in response to
Fig 6. Plasma sCD127 concentrations associated with IL-7-induced activation of CD4+ T-cells in SIV-infected, ART-treated Rhesus
macaques. These effects were observed frequently among animals in this study, yet varied by IL-7 treatment cluster (depicted by arrows). (A-D)
Increases of sCD127 paralleled the changes in Ki67+CD4+ TN and TCM cell numbers in 3 out of 4 animals evaluated, specifically (A) RM22657, (B)
RM23686 and (C) RM23750.
https://doi.org/10.1371/journal.pone.0188427.g006
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an IL-7 cluster. Carini et al. were the first to show that viral control was associated with
sCD127 release. They demonstrated that PBMC from untreated HIV+ individuals lacking CTL
responses with IL-7 stimulation released more sCD127 in vitro than those of individuals with
detectable CTL responses[24]. Likewise, we have previously shown that increased plasma
sCD127 concentrations in untreated HIV infection positively correlated with plasma IL-7 con-
centrations, linking chronic viral infection and IL-7 with sCD127 release[23]. Other reports of
sCD127 concentrations in HIV infection have found either decreased concentrations or simi-
lar concentrations, when compared to healthy individuals[38, 39]. Janot-Sardet et al., evaluated
IL-7 therapy in HIV infection yet found not change in sCD127 concentration. It should be
noted that those study subjects were ART-treated and aviremic (>12 months) and were
administered recombinant glycosylated human IL-7 at a 3x lower dose than our study, and
this was administered weekly for only 3 weeks, compared to our 3 clusters[40]. Therefore, mul-
tiple inherent differences in the study design make comparison of the present data to that
study problematic. What is notable of the data reported herein is that increases in sCD127 con-
centrations and its association with increased effects on T-cells were more pronounced when
SIV infection was not controlled. There is increasing evidence to suggest that sCD127 concen-
trations may have a role in chronic disease. The CD127 gene has distinct genetic features that
suggest it may be a biomarker for the progression of chronic immune-based diseases, as ini-
tially discovered in multiple sclerosis[41–43]. In addition to this, we and others have reported
associations of sCD127 concentrations with disease in HIV infection[18, 22–25], Mycobacte-
rium tuberculosis infection[44], stem cell transplantation[45, 46], T-cell acute lymphoblastic
leukemia[47], Type 1 diabetes (T1DM)[48] and rheumatoid arthritis[49]. In addition, the
Fig 7. Plasma sCD127 concentrations associated with IL-7-induced activation of CD4+ T-cells in SIV-infected, ART-treated Rhesus
macaques. The concentration of plasma sCD127 increased as the number of activated CD8+ TEM cells increased in all 4 animals treated with IL-7. Total
number of IL-7-treated animals in which T-cell activation data (Ki67 assay) was available: n = 4 (data for the 5th animal in this group is not available for
this parameter of the study). The clustered administration of IL-7 is indicated on the x-axis by groups of three arrows.
https://doi.org/10.1371/journal.pone.0188427.g007
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presence of sCD127 has been associated with enhanced IL-7-mediated homeostatic prolifera-
tion and exacerbation of existing T-cell-derived autoimmunity[27]. Similarly, IL-7-mediated
anti-tumour activity of T-cells was significantly enhanced in the presence of sCD127[50].
As the Leone et al. study, and that of others, have shown, IL-7 therapy in the context of
ART-treated SIV/HIV results in immunorestorative effects on T-cells[7, 8, 33]. This is poten-
tially an important gain, given that viral suppression does not result in complete immune
reconstitution of the T-cell compartment. IL-7 therapy can improve CTL activity (e.g. "IFN-
γ), viral clearance and mitigate associated liver pathology in a murine model of chronic LCMV
infection[51], a system sharing some similarities to HIV and HCV infection. In this study, we
found associations suggesting that sCD127 may be contributing to the effects of IL-7 therapy
on T-cells and therefore, perhaps sCD127 is a biomarker for immunorestorative effects. The
challenge for the eradication of HIV infection is the elimination of the latent viral reservoir.
Recent in vitro findings have demonstrated that IL-7 may be reactivating the HIV reservoir in
memory CD4+ T-cells in otherwise virally-controlled settings[52]. This follows a “kick and
kill” HIV cure strategy whereby inducing viral replication in the reservoir cells enables antivi-
ral drug elimination of these final sources of virus[53]. Such effects with IL-7 therapy were
observed in the first HIV trials with this cytokine, as transient viral blips were recorded follow-
ing cytokine administration[7, 8]. Whether sCD127 has a role in the immunorestorative and
viral reservoir reactivation effects of IL-7 therapy through its enhancement of T-cell numbers
is not known.
While increases in plasma sCD127 concentrations correlated with, or were coincidental
with several IL-7-induced outcomes measured in this model, whether sCD127 concentrations
directly contributed to the outcomes achieved is not known[34]. Despite being discovered
more than 20 years ago, the role of sCD127 in mediating IL-7 activity has not been well
Fig 8. IL-7 therapy-mediated effects on T-cell survival is associated with increases in plasma sCD127 concentrations. The concentration of
plasma sCD127 was compared to T-cell survival, as assessed by BrDU uptake. Starting at 142 d.p.i, animals received 4 daily injections of BrDU. The
number of circulating BrDU+ CD4+ and CD8+ T-cells was determined every 7 days until 373 d.p.i. (A) The survival profiles of T-cells in each of the SIV-
infected, ART-treated Rhesus macaques in the control group are shown.
https://doi.org/10.1371/journal.pone.0188427.g008
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characterized[37], and hence the extent to which it contributes to disease remains unclear. In
our early research, experiments using either native or recombinant sCD127 demonstrated a
reduction of IL-7-mediated CD8+ T-cell signaling and proliferation in vitro[23]. In vivo experi-
ments reported that the release of sCD127 at the onset of Type 1 diabetes was associated with
inhibiting IL-7-mediated signaling and cell proliferation[54]. This was thought to be mediated
in part by increased glycosylation of sCD127 during hyperglycemia, impairing the ability of
sCD127 to inhibit IL-7 activity[54]. However, our more recent studies demonstrate that pre-
incubation of sCD127 with IL-7 increased cytokine activity on CD8+ T-cells, and enhanced
their cellular function[26]. Other studies have also shown a similar augmentation of T-cell
activity in tumour models and in the context of autoimmunity[27, 50]. Taken together, these
studies confirm previous suggestions that sCD127 may act as a either a decoy receptor or
extending cytokine action by prolonging the half-life of its ligand[55]. The data presented in
our study indicates that sCD127 is likely not directly mediating the IL-7-mediated effects. Fur-
ther studies are required to more definitively demonstrate the biological function of this
secreted receptor.
Fig 9. IL-7 therapy-mediated effects on T-cell survival is associated with increases in plasma sCD127 concentrations. T-cell survival graphs for
all animals in the IL-7 treatment group. In all plots, an arbitrary, yet common crossing point of 5 BrDU+ cells/μl of blood is indicated by a dotted line. The
clustered administration of IL-7 is indicated on the x-axis by groups of three arrows and the first day of the BrDU injections is also indicated.
https://doi.org/10.1371/journal.pone.0188427.g009
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The bioavailability limitations of administered IL-7 are typically thought to be mediated by
cytokine half-life or its consumption by altered mCD127 expression[27]. In this study, the
overall proportion of mCD127+ T-cells was similar prior to each IL-7 cluster, hence this was
thought not to play a role in mediating IL-7 effects[34], although others have reported that IL-
7 administration to macaques results in difficulties in detecting CD127 expressing cells due to
CD127 down-regulation and IL-7 blocking of the CD127 receptor[56, 57]. Based on findings
by Okoye et al, which demonstrated that naïve, memory, central memory, transitional memory
and effector memory CD8+ T-cells all express Ki67 in response to IL-7 therapy in both adult
and aged macaques[58], one can infer which subsets are responses to the cytokine. Similarly,
our data indicated that TN and TEM cell subsets expressed the most Ki67, and hence would
presumably be those increasing in association with sCD127 levels (Fig 5B). Dereuddre-Bosquet
et al determined that approximately 64% of CD3+CD4+ and 47% of CD3+CD8+ T-cells express
mCD127 in uninfected, untreated macaques, but that IL-7 therapy resulted in a competition
for the detection of CD127+ cells[57]. Consideration of the hierarchical expression pattern of
mCD127 (i.e. memory cells> naïve cells> effector cells) informs the potential effects of IL-7
on distinct cell subsets[59] and the responsive cells in this study, namely TN and TCM cells,
expressed high levels of mCD127 (approx. 70% and 65%, respectively) before SIV infection.
The IL-7-induced migration of T-cells from the blood to organs such as lymphoid organs and
the gut, as has been reported previously, should also be considered[33]. And lastly, similar to
HIV infection, one must contend with the fact that SIV infection also results in the downregu-
lation of mIL-7Rα expression while3 IL-2 receptor γ expression is also decreased[60].
In conclusion, this study has demonstrated that sCD127 concentrations are associated with
the immunorestorative outcomes of repetitive IL-7 therapy in SIV-infected Rhesus macaques
receiving ART. There was significant evidence that increases in sCD127 correlated with
increased T-cell numbers and survival. This suggests that sCD127 may have a role in the
replenishment of the T-cell pool with IL-7, although further studies are required. Lastly, the
magnitude and frequency of increased concentrations of plasma sCD127 concentrations
in> 1 cluster of IL-7 treatment was more pronounced among animals that lost, or lacked viral
control. Highlighting such relationships provides insight into the design of immunorestorative
strategies for HIV infection, while building an awareness of the effects this may have on
“Cure”. Therefore, this study provides insights regarding the ability of sCD127 to be utilized as
an indicator of IL-7 associated therapies that might be utilized in future HIV-infected patients.
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